Literature DB >> 18840986

[Successful treatment with 5-fluorouracil and cis-dichlorodiammineplatinum combined with 60Gy of radiation in a case of advanced esophageal cancer complicated with chronic renal failure treated with hemodialysis].

Yoko Arai1, Tsuneo Oyama, Kinichi Hotta, Akihisa Tomori, Yoshinori Miyata.   

Abstract

5-Fluorouracil(5-FU)and cis-dichlorodiammineplatinum(CDDP)combined with 60Gy of radiation was administered to a 65-year-old man with advanced esophageal cancer complicated with chronic renal failure treated with hemodialysis(HD). Continuous infusion of 5-FU 680mg/m(2) on Days 1-5 and 8-12, and drip infusion of CDDP 40mg/m(2) on Days 1 and 8 were administered twice with a 5-week interval. The CDDP dosage was reduced to 40% and HD was started 30 minutes after CDDP administration. Concurrent radiotherapy was started on Day 1 at 2Gy/d for 5d/week. The concentration of both free CDDP and total CDDP was measured using the atomic absorption method after the second treatment period. The area under the curve(AUC)of free CDDP was 3.3microg x h/ml. Both Grade 4 anemia and Grade 3 leukopenia were observed, but the renal failure did not progress. All toxicities were tolerable and the CDDP dose reduction and HD method were appropriate for the patient.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18840986

Source DB:  PubMed          Journal:  Nihon Shokakibyo Gakkai Zasshi        ISSN: 0446-6586


  2 in total

Review 1.  Guidelines for treatment of renal injury during cancer chemotherapy 2016.

Authors:  Shigeo Horie; Mototsugu Oya; Masaomi Nangaku; Yoshinari Yasuda; Yasuhiro Komatsu; Motoko Yanagita; Yuko Kitagawa; Hiroyuki Kuwano; Hiroyuki Nishiyama; Chikashi Ishioka; Hiromasa Takaishi; Hideki Shimodaira; Akira Mogi; Yuichi Ando; Koji Matsumoto; Daisuke Kadowaki; Satoru Muto
Journal:  Clin Exp Nephrol       Date:  2018-02       Impact factor: 2.801

2.  A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis.

Authors:  Jennifer R Eads; Jan H Beumer; Lavinia Negrea; Julianne L Holleran; Sandra Strychor; Neal J Meropol
Journal:  Cancer Chemother Pharmacol       Date:  2015-12-21       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.